56 results about "Virus host" patented technology

The invention provides a dry powder composition for a zooblast culture medium. Compared with the prior dry powder composition for the zooblast culture medium, the dry powder composition provided by the invention reduces the serum dosage of animals by introduction of recombinant protein or animal origin compositions, the dry powder composition for the zooblast culture medium can be matched with low-content animal serum for use without additional introduction of protein compositions (such as the recombinant protein, plant protein or the animal origin compositions including cytokines and so on), and has the same or better function on promoting the growth of zooblast compared with high-content animal serum, so that the dry powder composition for the zooblast culture medium does not generate side effects along with the protein compositions, and has good safety and low cost. Cells cultured by the dry powder composition for the zooblast culture medium have small difference for different batches, low cost and good safety, are favorable for separating downstream products of the cells, and are suitable to be used for virus hosts, expression vectors and so on of biological products and other biological products.

The present invention is directed to genetically engineered, membrane-enveloped viruses with deletion mutations in the protein transmembrane domains. Also provided are viral vaccines based on the engineered viruses, methods of producing and using such vaccines.

The invention provides a method for culturing baby hamster kidney (BHK) 21 cell in a serum-free way, which leads the BHK 21 cell to be inoculated into a cell culture medium for culturing, wherein the cell culture medium comprises a basic culture medium and further comprises 100-200g/100L of soy protein, 100-200g/100L of pea protein, 100-200g/100L of broad bean protein, 0-100g/100L of potato protein, 0-200g/100L of wheat gluten protein and 50-100g/100L of rice protein by taking the volume of solvent of the culture medium as reference. In addition, the invention also provides a vaccine (such asrabies vaccine and foot-and-mouth disease vaccine) preparation method comprising the method for culturing the BHK 21 cell. The BHK 21 cell cultured by the culture medium containing the vegetable protein is high in culture density, beneficial to separating down-stream products of the cells, low in cost, small in batch difference, good in safety and suitable for producing virus host, expression vector and the like of biological products such as vaccine and the like.

The invention provides a method for culturing an animal cell. The method does not need to introduce extra protein component outside animal serum (such as recombinant protein, vegetable protein or animal source component like cytokine); because using low content animal serum can achieve the same or even better effect as using high content animal serum in the aspect of promoting growth of the animal cell, the method for culturing the animal cell does not produce side effects accompanied by the protein component outside the animal serum, and has the advantages of good security and low cost. In addition, the method for culturing the animal cell uses less animal serum, therefore cells cultured by the method have little difference between different batches, low cost, good security, are good for separating cell downstream products, and are suitable to be virus hosts, expression vectors of biological products like vaccines.

The invention provides a serum-free animal cell culture medium dry powder and a preparation method thereof; the serum-free animal cell culture medium dry powder comprises basic culture medium dry powder and further comprises 100-200g/100L of soy protein, 100-200g/100L of pea protein, 100-200g/100L of broad bean protein, 0-100g/100L of potato protein, 0-200g/100L of wheat gluten protein and 50-100g/100L of rice protein by taking the volume of solvent of the culture medium as reference. The invention also provides a liquid serum-free animal cell culture medium containing the serum-free animal cell culture medium dry powder and a preparation method thereof. The cells cultured by the culture medium containing the vegetable protein are high in culture density, beneficial to separating down-stream products of the cells, low in cost, small in batch difference, good in safety and suitable for producing virus host, expression vector and the like of biological products such as vaccine and the like.

The invention generally provides therapeutic and prophylactic compositions that include a replication defective mutant HSV-2 virus having a mutation in a viral host shut-off protein, a herpes simplex virus having a mutation in a viral host shut-off protein and two additional mutations that render the virus replication defective, and related methods.

A method for cloning the virus host factor gene by use of dual-chain RNA low-poison virus (chesnut blight bacterium system) includes such steps as light irradiating to induce the generation of conidia of chestnut phytophthora disease bacteria, inducing to obtain mutant, purifying, discriminating the virus carried by said mutant, testing the activity of its mRNA precursor, transforming and complementing of said mutant, discriminating, sequentially the exogenous DN'A fragment of the transformed plasmid with complem entary power, and configuring gene map.

Described are single-stranded new sequences of TT viruses, rearranged TTV sequences and hybrid molecules of a specific TT virus sequence and host cell DNA that are capable of replicating autonomously for use in diagnosis, prevention and treatment of diseases like cancer and autoimmunity. In addition, it relates to the use of such molecules as gene vectors and artificial chromosomes.

The invention relates to a universal strong promoter among species derived from white spot syndrome virus and an application thereof. The invention provides the universal strong promoter among the species derived from the white spot syndrome virus, two primers of the strong promoter, an expression vector of the strong promoter and recombinant host cells of the expression vector. The promoter is an immediate early gene promoter of the white spot syndrome virus and can high-efficiently start the expression of downstream genes in insect cells, mammalian cells and the white spot syndrome virus host cells (including cells of crayfish and shrimp). The recombinant host cells are obtained by transfection of the expression vector containing the universal strong promoter among the species derived from the white spot syndrome virus in the host cells, and the recombinant host cells can express target protein genes controlled by the universal strong promoter among the species derived from the white spot syndrome virus.

The invention provides a European eel kidney cell line EK and application thereof, belonging to the technical field of animal cell culture. The kidney cell line of Anguilla anguilla is deposited as CCTCC NO: C2018160. The cell line is a fibroblast type cell, which is primary cultured by tissue block adherence method and passaged by trypsin digestion method. The kidney cell line EK in L-15 containing 8% of fetal bovine serum has the optimum state during culture at 26 DEG C.. The typical morphology of fibroblasts can be maintained after 65 passages in vitro. The karyotype of fibroblasts is aneuploid. After cryopreservation and resuscitation, the survival rate of fibroblasts is 85%, and the fibroblasts grew rapidly. The cell line EK can be used to construct the expression model of exogenous gene, can also be used as a host cell for viral isolation and other etiological and immunological research.

The invention discloses a KMB17 cell-adapted strain for the II type dengue virus and a preparation method thereof. The epidemic II type dengue virus strain can be adapted to the human embryo lung diploid cell KMB17 to obtain the cell-adapted strain with stable passage and high virus amplification capacity, and purified strains with strong virulence and purity are obtained through plague purification; after identification, the virus purified strains maintain basic biological characteristics of original strains, are provided with good antigenicity, and are capable of performing II type dengue virus amplification with the human embryo lung diploid cell KMB17 as the matrix, limitation of host cells of the II type dengue virus is broken, a new thinking with China's regional characteristics is opened up for research of the vaccine for preventing the dengue virus, the function is laid for research of inactivation of the II type dengue virus and attenuated live vaccines, feasibility of mass production is provided simultaneously, and the research and development of the vaccine can produce great economic value and social benefits.

The invention relates to a purification method for a rabies virus inactivated vaccine. The method includes the following steps: (1) inoculating and cultivating rabies vaccine strains by using Vero cells as virus hosts, and harvesting a virus concentrate; (2) performing virus inactivation; and (3) preparing the purified inactivated rabies vaccine by using molecular sieve chromatography and anion exchange chromatography. The method provided by the invention does not add any chemical purification agent to the vaccine, the operation is simple, the process consistency is good, and the virus antigencan be prevented from being diluted in the purification process.

Target cell specificity of delivery vectors is provided by incorporation of a target cell specific binding domain by the use of any binding domain, which binds specifically to a binding site on the target cell. The binding site may be endogenous to the target cell, provided by engineering the target cell, or a suitable binding site may be associated with the target cell. Target cell may also be associated with a CVR polypeptide to provide specificity for the delivery vector. The association of the CVR polypeptide confers target cell specificity for a second virus host cell range, which specificity differs from the viral host cell range of the endogeneous target cell or animal host cell viral receptors. The CVR polypeptide may thus comprise a chimeric virus binding site which binds a second virus env binding domain specific for a second virus host cell range, selected from at least one of the group consisting of amphotropic, polytropic, xenotropic, ecotropic and tissue specific.

The present invention describes ways to identify HLA allele-specific epitopes that result from HLA restriction of antigen-specific cellular immune responses. The invention employs a combination of bioinformatics and functional assays to systematically identify and classify CTL mutations to determine correlates of virus-host interactions Peptides representing HLA allele-specific epitopes are provided as well as methods for validating HLA-restricted epitopes and methods for measuring T cell responses.

The present invention provides a novel branched-chain sialose molecule represented by the following formula (I), which is capable of preventing type A from all humans and animals as a host-wide variation or antigenic variation against influenza virus Substances used for adsorbents such as pharmaceuticals infected with influenza virus and influenza B virus, and filters for virus removal. (In the formula, NeuAc represents N-acetylneuraminic acid in which the hydroxyl group, carboxyl group and amide group of the NeuAc may be chemically modified by halogen, alkyl group or acyl group in the same or different ways, Hex represents hexose, HexNAc represents acetylhexosamine , R is a matrix selected from hydrogen atoms, hydrocarbon chains, sugar chains, lipids, proteins, and synthetic polymers, and R may also have substituents. In addition, the combination of N-acetylneuraminic acid and hexose may be naturally occurring The ortho-glycosidic bond may be a chemically transformed bond such as S-glycosidic or Se-glycosidic bond.)

The invention discloses an I-type dengue virus KMB17 cell adapted strain and a preparation method thereof. A popular I-type dengue virus strain can be adapted onto a human embryo lung cell KMB17 for growing to obtain the cell adapted strain which stably goes down to posterity on the KMB17 cell and is strong in virus replication capacity, and the purified adapted strain with high purity is obtained by virtue of a method of purifying bacteriophage plaque by many times. According to a series of identifications on the virus, the I-type dengue virus keeps good antigenicity and basic biological characteristics of the original virus strain. According to the invention, the I-type dengue virus KMB17 cell adapted strain can carry out I-type dengue virus amplification by taking the human embryo lung cell KMB17 as substrate, breaks through limitation of an I-type dengue virus host cell, and lays a foundation for quickening developing a novel idea for researching a dengue virus prophylactic vaccine, and developing I-type dengue virus inactivated and attenuated live vaccines; meanwhile, large-scale production feasibility is achieved.

The present invention discloses a cell labeling method and an application thereof in MRI imaging of rare cells. The cell labeling method uses a magnetic micron particle marked by a carrier containingquantum dots to infect cells for labeling and the carrier is a virus-like particle or a targeting group; the virus-like particle is self-assembled by virus capsid proteins fused with cell-penetratingpeptide fragments; and cell-penetrating peptides are connected to the targeting group. The fluorescent magnetic micron particle used in the labeling method contains the cell penetrating peptides, canintroduce MPIO into a variety of cells in a low-toxicity and high-efficiency manner, realizes targeted positioning and precise treatment of virus host cells or tumors, realizes a treatment mode integrating multi-modal diagnosis and treatment, and thus improves a treatment effect of the tumors. Long-term in vivo tracking of the rare cells in vivo is realized, MRI imaging is conducted, the efficientand reliable method for studying a behavior mechanism of the rare cells in body is provided, and the method provides reliable technical means for in vivo imaging for studying cancer invasion and metastasis mechanisms.

The invention relates to the field of virology, and particularly provides application of CCND1 in preparation of an avian retrovirus production enhancer; the CCND1 is cyclin D1 (G1/S-specific cyclin-D1, CCND1); the nucleotide sequence of the CCND1 is as shown in SEQ ID NO.1; the coded amino acid sequence of the CCND1 is as shown in SEQ ID NO.2; the inventor establishes a preparation and use method of the CCND1 as the avian retrovirus production enhancer for the first time; the mechanism of the CCND1 for promoting replication of the avian retrovirus is defined for the first time: the CCND1 regulates and controls the period of a virus host cell to be converted from a G1 period to an S period; and the S period is prolonged, so that replication of the retrovirus is promoted.